Allos's Folotyn gets FDA panel nod for lymphoma
03 September 2009
Sue Sutter
Allos Therapeutics' Folotyn (pralatrexate) should receive accelerated approval for relapsed or refractory peripheral T-cell lymphoma (PTCL), the US
FDA's oncology experts have said. The advisory panel voted 10 to four that a 27% response rate and the durability of responses seen in a pivotal, single-arm...
Please Login to read the full article.
03 September 2009
Sue Sutter
Please Login to read the full article.
RELATED CONTENT
NEWS
- Allos' Folotyn extends PFS and defers resistance to other drugs in lymphoma
- Allos' Folotyn falls at EU regulator: casts doubt over future US sales
- ODAC backs ApoPharma's iron chelator, but lacks harmony on prostate cancer trials
- AMAG, Allos to merge – but will it really bring sales synergies for Feraheme, Folotyn?
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
